Hongyang Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongyang Duan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wang
National Center for Nanoscience and Technology
3 shared publications - Changliang Liu
CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, People's Republic of China
2 shared publications Jiaxi Peng
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology Beijing 100190 China
2 shared publicationsWenzhe Li
CAS Key Laboratory of Standardization and Measurement for Nanotechnology
2 shared publications- Yanlian Yang
National Center for Nanoscience and Technology
2 shared publications Yuchen Lin
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology Beijing 100190 China
2 shared publications
Latest Publications
- Open Access
- 30 November 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (70) , 39948-39956
Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer
The metastasis of breast cancer is one of the main factors resulting in the high fatality of patients. Although many antagonists have been developed to inhibit the metastasis of breast cancer, their practical application has been limited because of the poor solubility of many chemotherapeutic drugs in the physiological environment. Herein, a complex of E5 peptide antagonist and acetylated PAMAM G5 (PAC80) has been constructed to enhance the solubility of the peptide antagonist. The E5 peptide antagonist has been designed and it was confirmed that it could specifically bind to CXCR4, which is a chemokine receptor involved in the metastasis of several types of cancers, in our previous work. The results demonstrated that PAC80 could significantly increase the solubility of the E5 peptide in the physiological environment, as well as the affinity of the E5 peptide to CXCR4-positive cell lines, and the inhibitory effect of the E5 peptide for cell migration in vitro. Meanwhile, the passive lung metastasis model of breast cancer was established and the anti-tumor metastasis of the PAC80–E5 complex was evaluated in vivo. The results show that the PAC80–E5 complex demonstrated excellent inhibition for the tumor metastasis at an E5 dosage of 10 and 20 mg kg−1. These effects indicate a feasible strategy to apply the PAC80–peptide complex in cancer therapies to improve the solubility and bioavailability.
- 30 November 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (70) , 39948-39956
Open AccessImproving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer
The metastasis of breast cancer is one of the main factors resulting in the high fatality of patients. Although many antagonists have been developed to inhibit the metastasis of breast cancer, their practical application has been limited because of the poor solubility of many chemotherapeutic drugs in the physiological environment. Herein, a complex of E5 peptide antagonist and acetylated PAMAM G5 (PAC80) has been constructed to enhance the solubility of the peptide antagonist. The E5 peptide antagonist has been designed and it was confirmed that it could specifically bind to CXCR4, which is a chemokine receptor involved in the metastasis of several types of cancers, in our previous work. The results demonstrated that PAC80 could significantly increase the solubility of the E5 peptide in the physiological environment, as well as the affinity of the E5 peptide to CXCR4-positive cell lines, and the inhibitory effect of the E5 peptide for cell migration in vitro. Meanwhile, the passive lung metastasis model of breast cancer was established and the anti-tumor metastasis of the PAC80–E5 complex was evaluated in vivo. The results show that the PAC80–E5 complex demonstrated excellent inhibition for the tumor metastasis at an E5 dosage of 10 and 20 mg kg−1. These effects indicate a feasible strategy to apply the PAC80–peptide complex in cancer therapies to improve the solubility and bioavailability.
- 9 June 2017
- Published by Wiley in Chinese Journal of Chemistry
- Vol. 35 (8) , 1270-1277
Allosteric Modulation of Human Serum Albumin Induced by Peptide Ligand
- 9 June 2017
- Published by Wiley in Chinese Journal of Chemistry
- Vol. 35 (8) , 1270-1277
Allosteric Modulation of Human Serum Albumin Induced by Peptide Ligand
- Open Access
- 18 April 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (34) , 21298-21307
Peptide-binding induced inhibition of chemokine CXCL12
The chemokine CXCL12, and its receptor CXCR4, have been recognized to be involved in various instances of cancer metastasis. The CXCL12/CXCR4 axis has emerged as a potential target for cancer therapy. Here, we demonstrate a designed peptide (W4) targeting CXCL12 with high binding affinity, and describe its significant inhibitory effect on the CXCL12/CXCR4 axis. We show that W4 has comparable binding affinity (KD = 5.7 × 10−8 M) to that of the antibody of CXCL12 (KD = 3.0 × 10−9 M) using the surface plasma resonance (SPR) technique. Upon introduction of W4, the circular dichroism (CD) spectra show that the α-helical structure of CXCL12 gradually transformed into a β-sheet and random coil. These effects lead to the significant inhibitory effects on the CXCL12/CXCR4 axis using the CXCR4-positive breast cancer cell lines MCF-7 and MDA-MB-231 and the leukemia cell lines HL-60 and U937 as models. The results show that W4 significantly inhibits CXCL12-induced cell migration of MCF-7, MDA-MB-231, HL-60 and U937 even to 20.0% when the mole ratio is 1 : 1, completely abolishing the effect of CXCL12. These effects may provide evidence of the modulating ligand–receptor interactions of peptides as anti-ligand molecules that differ from the traditional receptor antagonists leading to therapeutic agents.
- 18 April 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (34) , 21298-21307
Open AccessPeptide-binding induced inhibition of chemokine CXCL12
The chemokine CXCL12, and its receptor CXCR4, have been recognized to be involved in various instances of cancer metastasis. The CXCL12/CXCR4 axis has emerged as a potential target for cancer therapy. Here, we demonstrate a designed peptide (W4) targeting CXCL12 with high binding affinity, and describe its significant inhibitory effect on the CXCL12/CXCR4 axis. We show that W4 has comparable binding affinity (KD = 5.7 × 10−8 M) to that of the antibody of CXCL12 (KD = 3.0 × 10−9 M) using the surface plasma resonance (SPR) technique. Upon introduction of W4, the circular dichroism (CD) spectra show that the α-helical structure of CXCL12 gradually transformed into a β-sheet and random coil. These effects lead to the significant inhibitory effects on the CXCL12/CXCR4 axis using the CXCR4-positive breast cancer cell lines MCF-7 and MDA-MB-231 and the leukemia cell lines HL-60 and U937 as models. The results show that W4 significantly inhibits CXCL12-induced cell migration of MCF-7, MDA-MB-231, HL-60 and U937 even to 20.0% when the mole ratio is 1 : 1, completely abolishing the effect of CXCL12. These effects may provide evidence of the modulating ligand–receptor interactions of peptides as anti-ligand molecules that differ from the traditional receptor antagonists leading to therapeutic agents.